• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Perpetua Medical

3.30 SEK13.7. klo 18.29
Less than 1K followers

PERP B

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-5.71 %
-14.73 %
+7.14 %
-34.00 %
-37.74 %
-34.26 %
-56.35 %
-98.12 %
-98.38 %

Perpetua Medical is a serial acquirer of companies in the healthcare sector. The company operates under a decentralized ownership model, where operations and decision-making take place in independent subsidiaries. The company name Perpetua (Latin for 'eternal') reflects the strategy of acquiring and long-term owning companies without any fixed time horizon. The head office is located in Uppsala.

Read more
Market cap
28.24M SEK
Turnover
-
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
21.8.
2026

Interim report Q2'26

20.11.
2026

Interim report Q3'26

26.2.
2027

Annual report '26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release18.06.2024 klo 23.15

Perpetua Medical AB: Perpetua Medical has entered a letter of intent regarding the acquisition of a majority stake in ES-Medical AB

Perpetua Medical
Regulatory press release14.06.2024 klo 14.15

Perpetua Medical AB: Resolutions from the Annual General Meeting 2024 in Pepetua Medcial

Perpetua Medical
Regulatory press release12.06.2024 klo 09.30

Perpetua Medical AB: Perpetua Medical is offered a loan facility of up to SEK 25 million

Perpetua Medical

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release17.05.2024 klo 09.30

Perpetua Medical AB: Perpetua Medical publishes interim report January - March 2024

Perpetua Medical
Regulatory press release15.05.2024 klo 10.30

Perpetua Medical AB: NOTICE OF ANNUAL GENERAL MEETING IN PERPETUA MEDICAL AB (PUBL)

Perpetua Medical
Regulatory press release24.04.2024 klo 09.30

Perpetua Medical AB (formerly Pharmacolog i Uppsala AB) appoints Camilla Lönn as CFO

Perpetua Medical
Press release23.04.2024 klo 09.30

Perpetua Medical AB (formerly Pharmacolog i Uppsala AB) announces its first day of trading on Nasdaq First North under its new company name

Perpetua Medical
Regulatory press release17.04.2024 klo 09.30

Nolsterby Invest AB has increased its holding further in Pharmacolog

Perpetua Medical
Regulatory press release16.04.2024 klo 17.42

Pharmacolog: ANNOUNCEMENT FROM THE EXTRAORDINARY GENERAL MEETING OF PHARMACOLOG I UPPSALA AB ON APRIL 16, 2024

Perpetua Medical
Regulatory press release16.04.2024 klo 16.07

Pharmacolog publishes annual report for 2023

Perpetua Medical
Regulatory press release08.04.2024 klo 09.30

Nolsterby Invest AB has increased its holding in Pharmacolog

Perpetua Medical
Regulatory press release04.04.2024 klo 09.30

Pharmacolog announces the appointment of Anders Hedlund as interim CEO

Perpetua Medical
Regulatory press release14.03.2024 klo 11.20

Pharmacolog: NOTICE TO EXTRAORDINARY GENERAL MEETING IN PHARMACOLOG I UPPSALA AB (PUBL)

Perpetua Medical
Regulatory press release14.03.2024 klo 11.15

Pharmacolog provides update on new business direction and proposes name change

Perpetua Medical
Regulatory press release01.03.2024 klo 13.55

Pharmacolog announces upcoming change in management

Perpetua Medical
Regulatory press release27.02.2024 klo 12.38

Warrants of series TO3 were subscribed to approximately 90.4 percent and Pharmacolog receives approximately SEK 2.3 million

Perpetua Medical
Regulatory press release20.02.2024 klo 15.10

Major shareholder in Pharmacolog exercises warrants of series TO3 for at least approximately SEK 0.54 million

Perpetua Medical
Regulatory press release20.02.2024 klo 09.30

The last day of trading with warrants of series TO3 in Pharmacolog is today, February 20, 2024

Perpetua Medical
Regulatory press release16.02.2024 klo 09.30

Year-end bulletin Pharmacolog 2023

Perpetua Medical
Regulatory press release15.02.2024 klo 09.30

Pharmacolog investigates the possibilities for a new business direction

Perpetua Medical